Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) saw strong trading volume on Friday . 142,987 shares were traded during trading, an increase of 8% from the previous session’s volume of 132,912 shares.The stock last traded at $8.46 and had previously closed at $8.50.

Several equities research analysts recently commented on the company. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Zacks Investment Research upgraded Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Thursday, April 21st. Royal Bank Of Canada cut their target price on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. Finally, BMO Capital Markets assumed coverage on Neos Therapeutics in a research report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $21.75.

The stock’s market cap is $137.18 million. The stock has a 50-day moving average of $9.77 and a 200 day moving average of $10.08.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.79) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.08. Equities research analysts expect that Neos Therapeutics Inc. will post ($4.88) EPS for the current year.

In other news, major shareholder Presidio Partners 2007, L.P. sold 20,367 shares of Neos Therapeutics stock in a transaction dated Wednesday, April 20th. The stock was sold at an average price of $9.98, for a total value of $203,262.66. Following the transaction, the insider now owns 1,575,419 shares in the company, valued at $15,722,681.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Alan L. Heller acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, May 19th. The stock was bought at an average price of $7.61 per share, for a total transaction of $76,100.00. Following the acquisition, the director now owns 379,888 shares of the company’s stock, valued at approximately $2,890,947.68. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP raised its position in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).